This article reviews the receptor pharmacology of neuroleptics, with a focu
s on newer drugs (e.g., risperidone, olanzapine, sertindole, quetiapine, an
d ziprasidone) in contrast to older compounds. All these newer compounds ar
e considered to be atypical neuroleptics based upon certain criteria, which
are reviewed. Several hypotheses about the molecular mechanisms that expla
in atypicality are considered. Finally, the in vitro receptor binding data
presented for these compounds are related to the therapeutic and adverse ef
fects of these drugs.